{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:08:13Z","timestamp":1785510493631,"version":"3.56.0"},"reference-count":83,"publisher":"Becaris Publishing Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    This study aimed to assess the cost-effectiveness of the annual volumetric-enabled low-dose computed tomography (LDCT) lung cancer screening (LCS), based on the NELSON screening outcomes, versus no screening for the asymptomatic high-risk population in Lithuania.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    The previously established model with a decision tree with an integrated state-transition Markov trace was adapted to assess the health benefits and the financial consequences of LCS from the Lithuanian healthcare system perspective. Individuals aged 50\u201374\u00a0years and with a smoking history underwent LCS with LDCT in the screening arm, and it was compared with the absence of screening across a lifetime horizon. The primary outcomes included the clinical benefits (lung cancer cases detected per stage and premature lung cancer deaths averted), direct costs (recruitment, diagnostic and treatment costs) of LCS implementation, quality-adjusted life years, life-years and the incremental cost-effectiveness ratio. One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to ascertain the result's robustness.\n                    <jats:bold>Results:<\/jats:bold>\n                    Annual LCS with volumetric-enabled LDCT for 170,808 eligible individuals in Lithuania resulted in 6117 additional early-stage (I and II) lung cancers detected and 1874 averted late-stage (III and IV) lung cancers, leading to 2606 premature lung cancer deaths averted and 21,639 life-years gained at an uptake rate of 46.5%. The incremental cost-effectiveness ratio was \u20ac1372 per quality-adjusted life year with incremental costs of \u20ac21.1\u00a0million and 15,391 quality-adjusted life years gained. The results were robust based on sensitivity and scenario analyses.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This study demonstrated that annual LCS with volumetric-enabled LDCT for a high-risk population could be cost-effective compared with no screening in Lithuania.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0034","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:46:38Z","timestamp":1784202398000},"source":"Crossref","is-referenced-by-count":0,"title":["Lung cancer screening in Lithuania: a cost-effectiveness analysis"],"prefix":"10.57264","volume":"15","author":[{"given":"Hilde ten","family":"Berge","sequence":"first","affiliation":[{"name":"Institute for Diagnostic Accuracy, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Piazza","sequence":"additional","affiliation":[{"name":"Institute for Diagnostic Accuracy, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"Ramaker","sequence":"additional","affiliation":[{"name":"Institute for Diagnostic Accuracy, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanqi","family":"Pan","sequence":"additional","affiliation":[{"name":"Institute for Diagnostic Accuracy, Groningen, The Netherlands"},{"name":"Unit of Global Health, Faculty of Medical Sciences, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titas","family":"Buk\u0161nys","sequence":"additional","affiliation":[{"name":"Market Access Department, AstraZeneca, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saulius","family":"Cic\u0117nas","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery &amp; Oncology, National Cancer Institute, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skaidrius","family":"Miliauskas","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giedre","family":"Smailyte","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Laboratory of Cancer Epidemiology, Vilnius, Lithuania"},{"name":"Department of Public Health, Institute of Health Sciences, Vilnius University, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolandas","family":"Zablockis","sequence":"additional","affiliation":[{"name":"Clinic of Chest Diseases, Immunology, &amp; Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania"},{"name":"Centre of Pulmonology &amp; Allergology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Zemaitis","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvardas","family":"Danila","sequence":"additional","affiliation":[{"name":"Clinic of Chest Diseases, Immunology, &amp; Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania"},{"name":"Centre of Pulmonology &amp; Allergology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_7_3_2","unstructured":"International Agency for Research on Cancer. Cancer Today. (2024). (Accessed 24 September 2025). https:\/\/gco.iarc.who.int"},{"issue":"9","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jtho.2020.02.029","article-title":"Lung cancer in Lithuania","volume":"15","author":"Gedvilait\u0117 V","year":"2020","unstructured":"Gedvilait\u0117 V, Danila E, Cic\u0117nas S, Smailyt\u0117 G. Lung cancer in Lithuania. J. Thorac. Oncol. 15(9), 1401\u20131405 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"e_1_3_7_5_2","unstructured":"Official Statistics Portal. Database Indicators. (Accessed 6 December 2022). https:\/\/osp.stat.gov.lt\/statistiniu-rodikliu-analize#\/"},{"key":"e_1_3_7_6_2","volume-title":"EU Country Cancer Profile: Lithuania 2025","author":"OECD\/European Commission","year":"2025","unstructured":"OECD\/European Commission. EU Country Cancer Profile: Lithuania 2025. EU Country Cancer Profiles, OECD Publishing, France (2025)."},{"issue":"1","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"107327481983608","DOI":"10.1177\/1073274819836085","article-title":"Lung cancer survival in Lithuania: changes by histology, age, and sex from 2003\u20132007 to 2008\u20132012","volume":"26","author":"Gedvilait\u0117 V","year":"2019","unstructured":"Gedvilait\u0117 V, Danila E, Cic\u0117nas S, Smailyt\u0117 G. Lung cancer survival in Lithuania: changes by histology, age, and sex from 2003\u20132007 to 2008\u20132012. Cancer Control 26(1), 1073274819836085 (2019).","journal-title":"Cancer Control"},{"issue":"5","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"The National Lung Screening Trial Research Team","year":"2011","unstructured":"The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365(5), 395\u2013409 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"de Koning HJ","year":"2020","unstructured":"de Koning HJ, van der Aalst CM, de Jong PA Reduced lung-cancer mortality with volume CT screening in a randomized trial. N. Engl. J. Med. 382(6), 503\u2013513 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1007\/s00330-022-08589-7","article-title":"Nationwide lung cancer screening with low-dose computed tomography: implementation and first results of the HUNCHEST screening program","volume":"32","author":"Kerpel-Fronius A","year":"2022","unstructured":"Kerpel-Fronius A, Monostori Z, Kovacs G Nationwide lung cancer screening with low-dose computed tomography: implementation and first results of the HUNCHEST screening program. Eur. Radiol. 32(7), 4457\u20134467 (2022).","journal-title":"Eur. Radiol."},{"issue":"9","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00432-012-1228-9","article-title":"Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round","volume":"138","author":"Becker N","year":"2012","unstructured":"Becker N, Motsch E, Gross ML Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round. J. Cancer Res. Clin. Oncol. 138(9), 1475\u20131486 (2012).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.lungcan.2007.08.040","article-title":"Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial","volume":"59","author":"Infante M","year":"2008","unstructured":"Infante M, Lutman FR, Cavuto S Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. Lung Cancer 59(3), 355\u2013363 (2008).","journal-title":"Lung Cancer"},{"issue":"7","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/JTO.0b013e31828f68d6","article-title":"Four-year results of low-dose CT screening and nodule management in the ITALUNG trial","volume":"8","author":"Pegna AL","year":"2013","unstructured":"Pegna AL, Picozzi G, Falaschi F Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. J. Thorac. Oncol. 8(7), 866\u2013875 (2013).","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/CEJ.0b013e328351e1b6","article-title":"Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial","volume":"21","author":"Pastorino U","year":"2012","unstructured":"Pastorino U, Rossi M, Rosato V Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur. J. Cancer Prev. 21(3), 308\u2013315 (2012).","journal-title":"Eur. J. Cancer Prev."},{"issue":"40","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20400","article-title":"The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer","volume":"20","author":"Field JK","year":"2016","unstructured":"Field JK, Duffy SW, Baldwin DR The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol. Assess. 20(40), 1\u2013146 (2016).","journal-title":"Health Technol. Assess."},{"key":"e_1_3_7_16_2","unstructured":"European Council - Council of the European Union. Council updates its recommendation to screen for cancer. (Accessed 12 December 2022). https:\/\/www.consilium.europa.eu\/en\/press\/press-releases\/2022\/12\/09\/council-updates-its-recommendation-to-screen-for-cancer\/"},{"issue":"12","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3390\/cancers17121956","article-title":"The Lithuanian Lung Cancer Screening Model: results of a pilot study","volume":"17","author":"Danila E","year":"2025","unstructured":"Danila E, Krynke L, Ciesi\u016bnien\u0117 A The Lithuanian Lung Cancer Screening Model: results of a pilot study. Cancers (Basel) 17(12), 1956 (2025).","journal-title":"Cancers (Basel)"},{"issue":"2","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2006.07.9202","article-title":"Use of modeling to evaluate the cost-effectiveness of cancer screening programs","volume":"25","author":"Knudsen AB","year":"2007","unstructured":"Knudsen AB, McMahon PM, Gazelle GS. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J. Clin. Oncol. 25(2), 203\u2013208 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/13696998.2023.2288739","article-title":"Cost-effectiveness of volume computed tomography in lung cancer screening: a cohort simulation based on Nelson study outcomes","volume":"27","author":"Pan X","year":"2024","unstructured":"Pan X, Dvortsin E, Baldwin DR Cost-effectiveness of volume computed tomography in lung cancer screening: a cohort simulation based on Nelson study outcomes. J. Med. Econ. 27(1), 27\u201338 (2024).","journal-title":"J. Med. Econ."},{"issue":"6","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061672","article-title":"Recommendations for implementing lung cancer screening with low-dose computed tomography in Europe","volume":"12","author":"Veronesi G","year":"2020","unstructured":"Veronesi G, Baldwin DR, Henschke CI Recommendations for implementing lung cancer screening with low-dose computed tomography in Europe. Cancers (Basel) 12(6), doi: 10.3390\/cancers12061672 (2020) (Epub ahead of print).","journal-title":"Cancers (Basel)"},{"key":"e_1_3_7_21_2","unstructured":"National Institute for Health and Care Excellence. Lung cancer: diagnosis and management. NICE Guideline NG122. (2019). https:\/\/www.nice.org.uk\/guidance\/ng122"},{"issue":"6","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1183\/09031936.00197712","article-title":"Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial","volume":"42","author":"Horeweg N","year":"2013","unstructured":"Horeweg N, Van Der Aalst CM, Vliegenthart R Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur. Respir. J. 42(6), 1659\u20131667 (2013).","journal-title":"Eur. Respir. J."},{"key":"e_1_3_7_23_2","unstructured":"Behmane D Lambot K Irs A. Baltic guideline for economic evaluation of pharmaceuticals (Pharmacoeconomic Analysis). (2002). (Accessed 2 December 2022). https:\/\/www.ispor.org\/heor-resources\/more-heor-resources\/pharmacoeconomic-guidelines\/pe-guideline-detail\/baltic-(latvia-lithuania-estonia)"},{"key":"e_1_3_7_24_2","unstructured":"Minister of Health Protection of the Republic of Lithuania. Regarding the approval of the description of the procedure for incorporation of medicinal products and medical aid equipment in the compensation lists and their change. (2022). (Accessed 26 July 2023). https:\/\/www.e-tar.lt\/portal\/lt\/legalAct\/TAR.E83CFAB10E7B\/asr"},{"issue":"4","key":"e_1_3_7_25_2","doi-asserted-by":"crossref","first-page":"e0266934","DOI":"10.1371\/journal.pone.0266934","article-title":"Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: a systematic review","volume":"17","author":"Iino H","year":"2022","unstructured":"Iino H, Hashiguchi M, Hori S. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: a systematic review. PLoS One 17(4), e0266934 (2022).","journal-title":"PLoS One"},{"issue":"1","key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"107327481987412","DOI":"10.1177\/1073274819874122","article-title":"Breast cancer screening program in Lithuania: interval cancers and program sensitivity after 7 years of mammography screening","volume":"26","author":"Steponaviciene L","year":"2019","unstructured":"Steponaviciene L, Vincerzevskiene I, Briediene R, Urbonas V, Vanseviciute-Petkeviciene R, Smailyte G. Breast cancer screening program in Lithuania: interval cancers and program sensitivity after 7 years of mammography screening. Cancer Control 26(1), 1073274819874122 (2019).","journal-title":"Cancer Control"},{"issue":"5","key":"e_1_3_7_27_2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3390\/cancers13051129","article-title":"National colorectal cancer screening program in Lithuania: description of the 5-year performance on population level","volume":"13","author":"Dulskas A","year":"2021","unstructured":"Dulskas A, Poskus T, Kildusiene I National colorectal cancer screening program in Lithuania: description of the 5-year performance on population level. Cancers (Basel) 13(5), 1129 (2021).","journal-title":"Cancers (Basel)"},{"issue":"12","key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/jcm9123826","article-title":"Prostate cancer screening with PSA: ten years' experience of population based early prostate cancer detection programme in Lithuania","volume":"9","author":"Patasius A","year":"2020","unstructured":"Patasius A, Krilaviciute A, Smailyte G. Prostate cancer screening with PSA: ten years' experience of population based early prostate cancer detection programme in Lithuania. J. Clin. Med. 9(12), 3826 (2020).","journal-title":"J. Clin. Med."},{"issue":"9","key":"e_1_3_7_29_2","first-page":"1401","article-title":"Lung cancer survival in Lithuania: changes by histology, age, and sex from 2003\u20132007 to 2008\u20132012","volume":"15","author":"Gedvilait\u0117 V","year":"2020","unstructured":"Gedvilait\u0117 V, Danila E, Cic\u0117nas S, Smailyt\u0117 G. Lung cancer survival in Lithuania: changes by histology, age, and sex from 2003\u20132007 to 2008\u20132012. J. Thorac. Oncol. 15(9), 1401\u20131405 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"e_1_3_7_30_2","volume-title":"World Population Prospects 2022, Summary of Results","author":"United Nations \u2013 Department of Economic and Social Affairs","year":"2022","unstructured":"United Nations \u2013 Department of Economic and Social Affairs. World Population Prospects 2022, Summary of Results. NY, USA (2022)."},{"key":"e_1_3_7_31_2","unstructured":"Public Hospital Fund under the Ministry of Health (VLK). Prices of compensatory services. (2022). (Accessed 5 December 2022). https:\/\/ligoniukasa.lrv.lt\/lt\/veiklos-sritys\/gydymo-istaigoms-ir-partneriams\/kompensuojamuju-paslaugu-kainos\/sveikatos-prieziuros-paslaugu-bazines-kainos%20%20%E2%80%9EBrangieji%20tyrimai%20ir%20proced%C5%ABros %20teikiami%20ambulatorin%C4%97mis%20s%C4%85lygomis%20bei%20taikant%20ilgalaik%C4%AF%20ir%20(ar)%20reabilitacin%C4%AF%20gydym%C4%85%E2%80%9C %202022"},{"issue":"6","key":"e_1_3_7_32_2","first-page":"480","article-title":"Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland","volume":"19","author":"Kanarkiewicz M","year":"2015","unstructured":"Kanarkiewicz M, Szcz\u0119sny TJ, Krysi\u0144ski J, Buci\u0144ski A, Kowalewski J, Paw\u0142owicz Z. Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland. Contemp. Oncol. 19(6), 480 (2015).","journal-title":"Contemp. Oncol."},{"issue":"4","key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus PE","year":"2017","unstructured":"Postmus PE, Kerr KM, Oudkerk M Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(Suppl. 4), iv1\u2013iv21 (2017).","journal-title":"Ann. Oncol."},{"issue":"2","key":"e_1_3_7_34_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria J-C","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378(2), 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_35_2","unstructured":"National Health Insurance Fund under the Ministry of Health. Medicines and medical aids (MPP). (Accessed 11 July 2023). https:\/\/ligoniukasa.lrv.lt\/lt\/veiklos-sritys\/gyventojams-1\/vaistai-ir-medicinos-pagalbos-priemones-mpp"},{"issue":"7","key":"e_1_3_7_36_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck M","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J. Clin. Oncol. 37(7), 537\u2013546 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"e_1_3_7_37_2","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis From KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel S","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G Updated analysis From KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 38(14), 1505\u20131517 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"e_1_3_7_38_2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski MA","year":"2021","unstructured":"Socinski MA, Nishio M, Jotte RM IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J. Thorac. Oncol. 16(11), 1909\u20131924 (2021).","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"e_1_3_7_39_2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok T","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann. Oncol. 31(8), 1056\u20131064 (2020).","journal-title":"Ann. Oncol."},{"issue":"10","key":"e_1_3_7_40_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269216315595203","article-title":"Estimating the cost of caring for people with cancer at the end of life: a modelling study","volume":"29","author":"Round J","year":"2015","unstructured":"Round J, Jones L, Morris S. Estimating the cost of caring for people with cancer at the end of life: a modelling study. Palliat. Med. 29(10), 899\u2013907 (2015).","journal-title":"Palliat. Med."},{"issue":"3","key":"e_1_3_7_41_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/0272989X15570364","article-title":"Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study","volume":"35","author":"Tramontano AC","year":"2015","unstructured":"Tramontano AC, Schrag DL, Malin JK Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study. Med. Decis. Making 35(3), 371\u2013387 (2015).","journal-title":"Med. Decis. Making"},{"issue":"5","key":"e_1_3_7_42_2","first-page":"484","article-title":"General population reference values for the EQ-5D-5L index in Poland: estimations using a Polish directly measured value set","volume":"131","author":"Golicki D","year":"2021","unstructured":"Golicki D. General population reference values for the EQ-5D-5L index in Poland: estimations using a Polish directly measured value set. Pol. Arch. Intern. Med. 131(5), 484\u2013486 (2021).","journal-title":"Pol. Arch. Intern. Med."},{"key":"e_1_3_7_43_2","unstructured":"National Cancer Institute of Lithuania (NVI). Cancer Registry. (2022). https:\/\/registras.nvi.lt\/lt\/"},{"issue":"10","key":"e_1_3_7_44_2","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.ejso.2020.08.013","article-title":"The progression of non-small cell lung cancer from diagnosis to surgery","volume":"46","author":"McPherson I","year":"2020","unstructured":"McPherson I, Bradley NA, Govindraj R, Kennedy ED, Kirk AJB, Asif M. The progression of non-small cell lung cancer from diagnosis to surgery. Eur. J. Surg. Oncol. 46(10 Pt A), 1882\u20131887 (2020).","journal-title":"Eur. J. Surg. Oncol."},{"issue":"10308","key":"e_1_3_7_45_2","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, Phase 3 trial","volume":"398","author":"Felip E","year":"2021","unstructured":"Felip E, Altorki N, Zhou C Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, Phase 3 trial. Lancet 398(10308), 1344\u20131357 (2021).","journal-title":"Lancet"},{"issue":"20","key":"e_1_3_7_46_2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage iii non\u2013small-cell lung cancer","volume":"377","author":"Antonia SJ","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D Durvalumab after chemoradiotherapy in stage iii non\u2013small-cell lung cancer. N. Engl. J. Med. 377(20), 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"e_1_3_7_47_2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn L","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379(23), 2220\u20132229 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"e_1_3_7_48_2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi L","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N. Engl. J. Med. 378(22), 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_49_2","unstructured":"Human Mortality Database. Lithuania. (2022). (Accessed 23 February 2024). https:\/\/www.mortality.org\/Country\/Country?cntr=LTU"},{"issue":"5","key":"e_1_3_7_50_2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/s41591-026-04292-y","article-title":"Implementation of the NHS England Lung Cancer Screening Programme over 5 years","volume":"32","author":"Lee RW","year":"2026","unstructured":"Lee RW, Nair A, Balata H Implementation of the NHS England Lung Cancer Screening Programme over 5 years. Nat. Med. 32(5), 1817\u20131826 (2026).","journal-title":"Nat. Med."},{"key":"e_1_3_7_51_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2022.05.005","article-title":"Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography","volume":"170","author":"Grover H","year":"2022","unstructured":"Grover H, King W, Bhattarai N, Moloney E, Sharp L, Fuller L. Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography. Lung Cancer 170, 20\u201333 (2022).","journal-title":"Lung Cancer"},{"key":"e_1_3_7_52_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison PT","year":"2020","unstructured":"Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin. Cancer Biol. 61, 167\u2013179 (2020).","journal-title":"Semin. Cancer Biol."},{"issue":"10","key":"e_1_3_7_53_2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening of epidermal growth factor receptor mutation in lung cancer","volume":"361","author":"Rosell R","year":"2009","unstructured":"Rosell R, Moran T, Queralt C Screening of epidermal growth factor receptor mutation in lung cancer. N. Engl. J. Med. 361(10), 958\u2013967 (2009).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_54_2","unstructured":"Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials \u2013 extrapolation with patient-level data. Report by the Decision Support Unit (2011). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395885\/pdf\/Bookshelf_NBK395885.pdf"},{"issue":"4","key":"e_1_3_7_55_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0272989X16670604","article-title":"Extrapolation of survival curves from cancer trials using external information","volume":"37","author":"Guyot P","year":"2017","unstructured":"Guyot P, Ades AE, Beasley M, Lueza B, Pignon J-P, Welton NJ. Extrapolation of survival curves from cancer trials using external information. Med. Decis. Making 37(4), 353\u2013366 (2017).","journal-title":"Med. Decis. Making"},{"key":"e_1_3_7_56_2","volume-title":"EU Country Cancer Profile: Poland 2023, EU Country Cancer Profiles","author":"OECD","year":"2023","unstructured":"OECD. EU Country Cancer Profile: Poland 2023, EU Country Cancer Profiles. OECD Publishing, France (2023)."},{"key":"e_1_3_7_57_2","unstructured":"OECD. Purchasing power parities (PPP). (Accessed 5 July 2023). https:\/\/www.oecd.org\/en\/data\/indicators\/purchasing-power-parities-ppp.html"},{"key":"e_1_3_7_58_2","unstructured":"Eurostat. HICP - inflation rate. (Accessed 16 March 2023). https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/tec00118\/default\/table?lang=en"},{"key":"e_1_3_7_59_2","unstructured":"Centers for Disease Control and Prevention. Health Effects of Cigarette Smoking. (2021). (Accessed 27 July 2023). https:\/\/www.cdc.gov\/tobacco\/data_statistics\/fact_sheets\/health_effects\/effects_cig_smoking\/index.htm"},{"issue":"69","key":"e_1_3_7_60_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22690","article-title":"Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation","volume":"22","author":"Snowsill T","year":"2018","unstructured":"Snowsill T, Yang H, Griffin E Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation. Health Technol. Assess. 22(69), 1\u2013276 (2018).","journal-title":"Health Technol. Assess."},{"key":"e_1_3_7_61_2","unstructured":"World Health Organization \u2013 International Agency for Research on Cancer. Estimated number of new cases in 2020 lung both sexes ages 50\u201374. (2020). (Accessed 3 August 2023). https:\/\/gco.iarc.fr\/today\/online-analysis-table?v=2020&mode=population&mode_population=countries&population=900&populations=900&key=asr&sex=0&cancer=15&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=10&ages_group%5B%5D=14&group_cancer=0&include_nmsc=0&include_nmsc_other=1"},{"issue":"6","key":"e_1_3_7_62_2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1183\/09031936.00197712","article-title":"Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial","volume":"42","author":"Horeweg N","year":"2013","unstructured":"Horeweg N, Van Der Aalst CM, Vliegenthart R Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur. Respir. J. 42(6), 1659\u20131667 (2013).","journal-title":"Eur. Respir. J."},{"key":"e_1_3_7_63_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.vhri.2022.10.002","article-title":"Shall we screen lung cancer with low-dose computed tomography? Cost-effectiveness in Hungary","volume":"34","author":"Nagy B","year":"2023","unstructured":"Nagy B, Szilberhorn L, Gy\u0151rb\u00edr\u00f3 DM Shall we screen lung cancer with low-dose computed tomography? Cost-effectiveness in Hungary. Value Health Reg. Issues 34, 55\u201364 (2023).","journal-title":"Value Health Reg. Issues"},{"key":"e_1_3_7_64_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2018.07.036","article-title":"Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: a modelling approach","volume":"124","author":"Hofer F","year":"2018","unstructured":"Hofer F, Kauczor H-U, Stargardt T. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: a modelling approach. Lung Cancer 124, 189\u2013198 (2018).","journal-title":"Lung Cancer"},{"key":"e_1_3_7_65_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2022.01.002","article-title":"Outstanding negative prediction performance of solid pulmonary nodule volume AI for ultra-LDCT baseline lung cancer screening risk stratification","volume":"165","author":"Lancaster HL","year":"2022","unstructured":"Lancaster HL, Zheng S, Aleshina OO Outstanding negative prediction performance of solid pulmonary nodule volume AI for ultra-LDCT baseline lung cancer screening risk stratification. Lung Cancer 165, 133\u2013140 (2022).","journal-title":"Lung Cancer"},{"key":"e_1_3_7_66_2","unstructured":"MacroTrends. World Smoking Rate 2000\u20132023. (2023). (Accessed 15 June 2023). https:\/\/www.macrotrends.net\/countries\/WLD\/world\/smoking-rate-statistics"},{"issue":"4","key":"e_1_3_7_67_2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/eurpub\/ckx035","article-title":"Burden of smoking in Lithuania: attributable mortality and years of potential life lost","volume":"27","author":"Liutkute V","year":"2017","unstructured":"Liutkute V, Veryga A, \u0160telemekas M, Midttun NG. Burden of smoking in Lithuania: attributable mortality and years of potential life lost. Eur. J. Public Health 27(4), 736\u2013741 (2017).","journal-title":"Eur. J. Public Health"},{"key":"e_1_3_7_68_2","volume-title":"Lithuania: Country Health Profile 2021, State of Health in the EU","author":"OECD\/European Observatory on Health Systems and Policies","year":"2021","unstructured":"OECD\/European Observatory on Health Systems and Policies. Lithuania: Country Health Profile 2021, State of Health in the EU, OECD Publishing, Paris\/European Observatory on Health Systems and Policies, Brussels (2021)."},{"key":"e_1_3_7_69_2","volume-title":"Chicago","author":"American Lung Association. State of Lung Cancer 2022","year":"2022","unstructured":"American Lung Association. State of Lung Cancer 2022. Chicago, IL, USA (2022). https:\/\/www.lung.org"},{"issue":"4","key":"e_1_3_7_70_2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2214\/AJR.20.23637","article-title":"Real-world lung cancer CT screening performance, smoking behavior, and adherence to recommendations: lung-RADS category and smoking status predict adherence","volume":"216","author":"Barbosa EJM","year":"2021","unstructured":"Barbosa EJM, Yang R, Hershman M. Real-world lung cancer CT screening performance, smoking behavior, and adherence to recommendations: lung-RADS category and smoking status predict adherence. AJR Am. J. Roentgenol. 216(4), 919\u2013926 (2021).","journal-title":"AJR Am. J. Roentgenol."},{"issue":"10","key":"e_1_3_7_71_2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/thoraxjnl-2020-214703","article-title":"Lung Screen Uptake Trial: results from a single lung cancer screening round","volume":"75","author":"Ruparel M","year":"2020","unstructured":"Ruparel M, Quaife SL, Dickson JL Lung Screen Uptake Trial: results from a single lung cancer screening round. Thorax 75(10), 908\u2013912 (2020).","journal-title":"Thorax"},{"issue":"5","key":"e_1_3_7_72_2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/JTO.0000000000000488","article-title":"Baseline characteristics and mortality outcomes of control group participants and eligible non-responders in the NELSON Lung Cancer Screening Study","volume":"10","author":"Yousaf-Khan U","year":"2015","unstructured":"Yousaf-Khan U, Horeweg N, Van Der Aalst C, Ten Haaf K, Oudkerk M, De Koning H. Baseline characteristics and mortality outcomes of control group participants and eligible non-responders in the NELSON Lung Cancer Screening Study. J. Thorac. Oncol. 10(5), 747\u2013753 (2015).","journal-title":"J. Thorac. Oncol."},{"issue":"24","key":"e_1_3_7_73_2","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.3390\/ijerph16245035","article-title":"The cost-effectiveness analysis of cervical cancer screening using a systematic invitation system in Lithuania","volume":"16","author":"Paulauskiene J","year":"2019","unstructured":"Paulauskiene J, Stelemekas M, Ivanauskiene R, Petkeviciene J. The cost-effectiveness analysis of cervical cancer screening using a systematic invitation system in Lithuania. Int. J. Environ. Res. Public Health 16(24), 5035 (2019).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"e_1_3_7_74_2","volume-title":"EU Country Cancer Profile: Lithuania 2023, EU Country Cancer Profiles","author":"OECD","year":"2023","unstructured":"OECD. EU Country Cancer Profile: Lithuania 2023, EU Country Cancer Profiles. OECD Publishing, France (2023)."},{"issue":"1","key":"e_1_3_7_75_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ijc.31043","article-title":"Status of implementation and organization of cancer screening in The European Union Member States\u2014Summary results from the second European screening report","volume":"142","author":"Basu P","year":"2018","unstructured":"Basu P, Ponti A, Anttila A Status of implementation and organization of cancer screening in The European Union Member States\u2014Summary results from the second European screening report. Int. J. Cancer 142(1), 44\u201356 (2018).","journal-title":"Int. J. Cancer"},{"key":"e_1_3_7_76_2","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-026-12525-4","article-title":"Recruitment strategies and outcomes in lung cancer screening programmes: a scoping review","author":"Djuric O","year":"2026","unstructured":"Djuric O, Venturelli F, Bassi MC Recruitment strategies and outcomes in lung cancer screening programmes: a scoping review. Eur. Radiol. doi: 10.1007\/s00330-026-12525-4 (2026) (Epub ahead of print).","journal-title":"Eur. Radiol."},{"issue":"4","key":"e_1_3_7_77_2","doi-asserted-by":"crossref","first-page":"53142","DOI":"10.31083\/BJHM53142","article-title":"How to translate quality standards into good lung cancer screening programmes: the UK experience","volume":"87","author":"Burzi\u0107 A","year":"2026","unstructured":"Burzi\u0107 A, O'dowd EL, Baldwin DR. How to translate quality standards into good lung cancer screening programmes: the UK experience. Br. J. Hosp. Med. (Lond.) 87(4), 53142 (2026).","journal-title":"Br. J. Hosp. Med. (Lond.)"},{"issue":"1","key":"e_1_3_7_78_2","doi-asserted-by":"crossref","first-page":"13872","DOI":"10.1038\/s41598-019-50407-6","article-title":"Concomitant screening of coronary artery disease and lung cancer with a new ultrafast-low-dose computed tomography protocol: a pilot randomised trial","volume":"9","author":"Gaudio C","year":"2019","unstructured":"Gaudio C, Tanzilli A, Mei M Concomitant screening of coronary artery disease and lung cancer with a new ultrafast-low-dose computed tomography protocol: a pilot randomised trial. Sci. Rep. 9(1), 13872 (2019).","journal-title":"Sci. Rep."},{"issue":"2","key":"e_1_3_7_79_2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.21037\/tlcr-20-746","article-title":"Added benefits of early detection of other diseases on low-dose CT screening","volume":"10","author":"Yip R","year":"2021","unstructured":"Yip R, Jirapatnakul A, Hu M Added benefits of early detection of other diseases on low-dose CT screening. Transl. Lung Cancer Res. 10(2), 1141\u20131153 (2021).","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"e_1_3_7_80_2","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00330-021-08422-7","article-title":"Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation","volume":"32","author":"Behr CM","year":"2022","unstructured":"Behr CM, Koffijberg H, Degeling K, Vliegenthart R, IJzerman MJ. Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation. Eur. Radiol. 32(5), 3067\u20133075 (2022).","journal-title":"Eur. Radiol."},{"key":"e_1_3_7_81_2","doi-asserted-by":"crossref","first-page":"100492","DOI":"10.1016\/j.lanepe.2022.100492","article-title":"Lung cancer trends and tumor characteristic changes over 20 years (2000\u20132020): results of three French consecutive nationwide prospective cohorts' studies","volume":"22","author":"Debieuvre D","year":"2022","unstructured":"Debieuvre D, Molinier O, Falchero L Lung cancer trends and tumor characteristic changes over 20 years (2000\u20132020): results of three French consecutive nationwide prospective cohorts' studies. Lancet Reg. Health Eur. 22, 100492 (2022).","journal-title":"Lancet Reg. Health Eur."},{"issue":"1","key":"e_1_3_7_82_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jtho.2021.07.031","article-title":"Screening for lung cancer in individuals who never smoked: an International Association for the Study of Lung Cancer Early Detection and Screening Committee Report","volume":"17","author":"Kerpel-Fronius A","year":"2022","unstructured":"Kerpel-Fronius A, Tammem\u00e4gi M, Cavic M Screening for lung cancer in individuals who never smoked: an International Association for the Study of Lung Cancer Early Detection and Screening Committee Report. J. Thorac. Oncol. 17(1), 56\u201366 (2022).","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"e_1_3_7_83_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/0969141316689111","article-title":"Evaluating efficacy of current lung cancer screening guidelines","volume":"24","author":"Nemesure B","year":"2017","unstructured":"Nemesure B, Plank A, Reagan L, Albano D, Reiter M, Bilfinger TV. Evaluating efficacy of current lung cancer screening guidelines. J. Med. Screen. 24(4), 208\u2013213 (2017).","journal-title":"J. Med. Screen."},{"issue":"5","key":"e_1_3_7_84_2","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.cllc.2016.01.001","article-title":"Proportion of non-small-cell lung cancer patients that would have been eligible for lung cancer screening","volume":"17","author":"Wu GX","year":"2016","unstructured":"Wu GX, Goldstein L, Kim JY, Raz DJ. Proportion of non-small-cell lung cancer patients that would have been eligible for lung cancer screening. Clin. Lung Cancer 17(5), e131\u2013e139 (2016).","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"e_1_3_7_85_2","doi-asserted-by":"crossref","first-page":"e230787","DOI":"10.1001\/jamanetworkopen.2023.0787","article-title":"Evaluation of lung cancer risk among persons undergoing screening or guideline-concordant monitoring of lung nodules in the Mississippi Delta","volume":"6","author":"Osarogiagbon RU","year":"2023","unstructured":"Osarogiagbon RU, Liao W, Faris NR Evaluation of lung cancer risk among persons undergoing screening or guideline-concordant monitoring of lung nodules in the Mississippi Delta. JAMA Netw. Open 6(2), e230787 (2023).","journal-title":"JAMA Netw. Open"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:24:35Z","timestamp":1785507875000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.57264\/cer-2026-0034"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0034","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"e260034"}}